Skip to main content

Table 2 Clinical features and radiological imaging scores in each treatment group from baseline and 3 months follow up in all patients with rheumatoid arthritis who had a 3-month follow-up visit

From: Assessment of 3-month changes in bone microstructure under anti-TNFα therapy in patients with rheumatoid arthritis using high-resolution peripheral quantitative computed tomography (HR-pQCT)

Total (n = 22)

MTX only group (n = 9)

MTX + anti-TNFα group (n = 13)

Mean ± SD

Baseline

3 Months

Changes

p value*

Baseline

3 Months

Changes

p value*

Disease activity

 Swollen joints

0.7 ± 1.0

1.6 ± 1.8

0.9 ± 1.8

0.184

14.5 ± 3.9

6.3 ± 4.8

-8.2 ± 6.6

<0.001

 Tender joints

0.7 ± 1.1

1.0 ± 1.3

0.3 ± 1.2

0.438

9.3 ± 6.2

4.4 ± 9.5

-4.9 ± 9.9

0.086

 Global assessment of patient

7.4 ± 15.3

16.3 ± 25.7

8.9 ± 19.6

0.210

62.2 ± 16.8

41.4 ± 31.2

-20.8 ± 26.6

0.015

 Physician

11.7 ± 10.9

14.1 ± 12.6

2.4 ± 9.4

0.459

42.8 ± 10.7

26.4 ± 12.1

-16.4 ± 18.2

0.005

 ESR unm h) (mm/h)

18.0 ± 22.3

21.0 ± I8.3

3.0 ± 10.9

0.435

32.2 ± 21.9

29.7 ± 21.6

-2.4 ± 12.9

0.490

 CRP tmg/L) (mg/L)

2.1 ± 1.1

4.6 ± 3.5

2.4 ± 2.9

0.034

21.9 ± 28.1

10.4 ± 9.8

-11.5 ± 22.2

0.088

 DAS-28-ESR

1.9 ± 0.9

2.6 ± 0.9

0.7 ± 1.2

0.106

5.7 ± 1.1

3.8 ± 1.2

-2.0 ± 0.9

<0.001

 DAS-28-CRP

l.8 ± 0.7

2.4 ± 0.8

0.6 ± 0.6

0.032

5.4 ± 0.9

3.5 ± 1.0

-I.7 ± 1.1

<0.001

 HAQ

0.5 ± 0.7

0.7 ± 0.8

0.2 ± 0.3

0.084

1.6 ± 0.7

1.0 ± 0.7

-0.6 ± 0.6

0.001

Modified SHARP score

 Total

4.7 ± 6.0

NA

NA

 

26.1 ± 42.0

NA

NA

 

 Erosion

1.6 ± 2.6

   

13.5 ± 26.8

   

 JSN

3.1 ± 4.9

   

12.5 ± 17.0

   

RAMRIS score

 JSN

0.2 ± 0.4

0.3 ± 0.7

0.1 ± 0.3

0.347

5.9 ± 8.4

5.9 ± 8.5

0.0 ± 0.4

<1.000

 Synovitis

3.2 ± 2.1

3.1 ± 2.1

-0.1 ± 0.9

0.598

4.9 ± 2.6

3.9 ± 2.3

-l.0 ± 2.1

0.126

 Bone erosion

2.6 ± 2.2

2.6 ± 2.6

0.0 ± 0.9

<1.000

20.5 ± 33.4

21.2 ± 33.3

0.6 ± 1.2

0.171

 Bone edema

4.9 ± 4.0

4.9 ± 3.6

0.0 ± 1.1

<1.000

9.7 ± 7.8

7.1 ± 6.3

-2.6 ± 3.8

0.105

  1. MTX methotrexate, TNFa tumor necrosis factor alpha, ESR erythrocyte sedimentation rate, CRP C-reactive protein, DAS-28 disease activity score 28, HAQ health assessment questionnaire score, JSN joint space narrowing, NA not applicable, RAMRIS Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis-magnetic resonance imaging scoring. *Paired t test